Nationales Gen- und Zelltherapieregister Deutschland e. V.

– central structure for collecting application data of innovative therapies

Successful establishment of the "Nationalen Gen- und Zelltherapieregisters Deutschland e. V." – central structure for collecting application data of innovative therapies

 

On June 30, 2025, leading medical societies and institutions founded the association "Nationalen Gen- und Zelltherapieregisters Deutschland e. V.." (nGCT-R). The founding members include the Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO), the Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), the Gesellschaft für Neuropädiatrie (GNP), the Gesellschaft für Thrombose- und Hämostaseologie (GTH), the Deutsche Gesellschaft für Gentherapie (DG-GT), the Berlin Institute of Health (BIH), and the INTEGRATE-ATMP Consortium. Registration in the register of associations took place on December 11, 2025.

The goal of the nGCT-R is to establish a permanent, central, digital registry infrastructure for the indication-independent recording of gene and cell therapies. This will create a reliable database for systematically evaluating the efficacy and safety of these innovative therapies and for strengthening research, care, and patient safety.

The founding of the association ensures the continued and sustainable development of the structures of the INTEGRATE-ATMP innovation fund project. In the future, the register will be expanded to include other specialist areas, and relevant stakeholders from politics, health insurance companies, government agencies, and industry will be systematically integrated.

 

A joint press release from the professional societies and the BIH was issued on January 21, 2026.